Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. The company has a market cap of $1.83 billion, a price-to-earnings ratio of -18.27 and a beta of 2.52. Providing a new perspective on ADHD in adults, this compelling book analyzes findings from two major studies directed by leading authority Russell A. Barkley. Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. Axsome Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020 Content Import Wed, 10/28/2020 - 07:01 Axsome Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020 October 28, 2020 This release is a backfill fro… He is also the founder of Antecip Capital LLC (formerly Versant Capital Management LLC). Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. These products are full of phytonutrients, antioxidants, and strong anti-inflammatory agents. Toxins present in food and the environment interfere with the body's ability to produce enough insulin. This is due to a specific ceramide toxin. Found insideThe Advances in Pharmacology series presents a variety of chapters from the best authors in the field. Products. Dr. Tabuteau is also the managing member of Antecip Bioventures II LLC. Transforming the CNS treatment approach by developing therapeutic options that improve patients’ lives in a meaningful way. 11.48% of Axsome Therapeutics' shares are currently sold short. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Axsome doesn't have any products on the market yet. "As part of the ongoing review of our NDA for AXS-05 . This book analyzes the scientific evidence for the addictive properties of food. With contributions from a range of international authors, the book takes the reader through each trial phase, technique, and issue. Found insideIT Shades Engage & Enable Axsome Therapeutics, Inc. a biopharmaceutical company developing novel therapies for the ... The Axsome DCC platform will utilize all Veeva Commercial Cloud products and services, including: multichannel Veeva ... Presenting a vivid historical account of the contributions that black psychiatrists have made to American psychiatry, this important book documents the growth and influence of the group in tandem with the advancement of the field as a whole ... Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. NEW YORK, Aug. 23, 2021 (GLOBE NEWSWIRE) - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S . Review of First Edition 'This book was a joy to read and a joy to review, All Pharmaceutical physicians should have a copy on their bookshelves; all pharmaceutical companies should have copies in their libraries. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. AXSM INVESTOR ALERT: Rosen Law Firm Encourages Axsome Therapeutics, Inc. Investors with Losses to Inquire About Class Action Investigation AXSM Posted on 08/09/2021 9643 Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Subscribe to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates. Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. Aug 10, 2021 8:31 AM PDT. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder. Biomedical Products in New York, NY. Axsome therapeutics has . AXS-05 is not approved by the FDA. Percentage. In April 2021, Axsome Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for AXS-05 for the treatment of major depressive disorder (MDD), and has granted the application Priority Review. Report Share. The company's lead product is the antidepressant . Post-Market 0.29 (1.09%) In Mirrors, Galeano smashes aside the narrative of conventional history and arranges the shards into a new pattern, to reveal the past in radically altered form. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. By clicking "accept all cookies", you consent to the storing of cookies on your device for improving site navigation, analyzing site usage, and assisting in our marketing efforts.Privacy Notice, © 2021 Axsome Therapeutics, Inc. All rights reserved. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. Over the last 12 months, Axsome Therapeutics's shares have ranged in value from as little as $50.05 up to $87.24. Axsome Therapeutics aims to become a fully integrated biopharmaceutical company that develops and commercializes differentiated products which increase the armamentarium of caregivers and improve the lives of patients. We are initiating coverage on Axsome therapeutics, an emerging company developing novel CNS products, with a Buy rating and a common stock price target of $15.24. Key Developments. Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive Disorder. This volume presents the most up-to-date findings and analysis on racial and social dynamics, with recommendations for ongoing research. 1. Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. Aug. 11, 2021 at 8:54 a.m. For more information, please . Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. This edition includes brand-new chapters on acupuncture, homeopathy, and therapies for substance dependence and weight management. The chapter on polypharmacy and side effect management addresses the growing issue of drug-drug interactions. Axsome Therapeutics NASDAQ Updated Sep 3, 2021 11:58 PM. Axsome Therapeutics, Inc.'s Email Format. . Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment . It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which . Axsome Therapeutics, Inc. announced that the U.S. Food and Drug Administration informed the Company in a teleconference on August 20, 2021, that its review of the new drug application for AXS-05 for the treatment of major depressive disorder would not be completed by the Prescription Drug User Fee Act target action date of August 22, 2021. Axsome Therapeutics price target cut to $55 from $118 at Mizuho, stock rated buy. The stock price of Axsome Therapeutics, a biopharmaceutical company focused on developing novel therapies for central nervous system conditions, has seen a 19% drop over the last twenty-one . The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. Available for Android and iOS devices. But this clinical-stage biotech has a lot going its way, and with a major potential catalyst in the near future, now might be an excellent time . Company to host conference call today at 8:00 AM Eastern. Cision Communication Cloud® . Take Axsome Therapeutics (NASDAQ:AXSM), a biotech whose shares have been struggling of late. Basics of covered call exit strategies -- definitions -- Why use exit strategies -- Mathematics of the 1-month contract period -- Key parameters to consider before expiration Friday -- Key parameters to consider on or near expiration Friday ... Major depressive disorder (MDD) is a debilitating, chronic, biologically-based disorder characterized by low mood, inability to feel pleasure, feelings of guilt and worthlessness, low energy, and other emotional and physical symptoms, and which impairs social, occupational, educational, or other important functioning. Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which . According to the National Institutes of Health, an estimated 7% of U.S. adults, or approximately 19 million, experience MDD each year1. AXSM 26.69 0.23 (0.85%). Get Verified Emails for Axsome Therapeutics, Inc. Employees. NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30, 2021. Axsome Thera (AXSM) Company Description Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30, 2021. Axsome has a balanced portfolio of clinical development stage as well as research stage products. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. Axsome Therapeutics, Inc. uses 2 email formats, with first_initial last (ex. AXS-05 (dextromethorphan and bupropion) FDA Approval History. Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of central nervous system disorders. Found insideThe American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia seeks to fulfill this need to improve the care of patients with dementia who are exhibiting ... The company has a debt-to-equity ratio of 0.50, a current ratio of 7.61 and a quick ratio of 7.61. AXS-05 is currently covered by more than 100 issued U.S. and international patents, with expiration dates out to 2040. Axsome Therapeutics is a CNS-focused pre-commercial stage biopharma with plans to file two New Drug Applications (NDA) in 2020 with the FDA, one for AXS-05 for the treatment of Major Depressive . Dr. Tabuteau has served as Chief Executive Officer of Axsome Therapeutics and Chairman of board of directors since our founding. Results from the 2019 National Survey on Drug Use and Health. Found insideOffering up-to-date information on brain imaging in mood disorders, this book is an invaluable resource for mental health professionals. Axsome Therapeutics' pipeline includes several late-stage candidates. 23.08.21 Buy 12.24%. For more information, please visit the Company’s website at axsome.com. Stopped prediction by Sievi for Axsome Therapeutics Inc. buy. Learn about our pipeline Axsome focuses on CNS conditions including depression, Alzheimer's disease agitation, migraine, narcolepsy and fibromyalgia. Found insideThe scientific and therapeutic implications of a new way of understanding a common disease. Axsome Therapeutics My Motley Fool colleague Cory Renauer views Axsome Therapeutics (NASDAQ:AXSM) as one of the top biotech stocks to buy this summer. Shares of Axsome Therapeutics stock opened at $48.59 on Monday. Beta is a measure of a share's volatility in relation to the market. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which . Focusing on applied and clinical examples, the Second Edition of PRINCIPLIES OF NEUROPSYCHOLOGY is an exciting and dynamic approach to neuropsychology that should inspire both students and teachers. The forward-looking statements include risks and uncertainties, including, but not limited to, the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of our ongoing clinical trials, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of our current product candidates; our ability to fund additional clinical trials to continue the advancement of our product candidates; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, our product candidates (including, but not limited to, whether potential filing issues or issues identified by FDA during the substantive review may impact the potential approvability of the Company’s NDA submission for AXS-05 in MDD or the timing of such approval, and whether the FDA will agree with the Company’s discontinuation of the bupropion treatment arm of the ADVANCE study in accordance with the independent data monitoring committee’s recommendations); the acceptance and approval by the FDA of an NDA for AXS-07 for the acute treatment of migraine in adults with or without aura, pursuant to our special protocol assessment for the MOMENTUM clinical trial; the potential for the ASCEND clinical trial, combined with the GEMINI clinical trial results, to provide a basis for approval of AXS-05 for the treatment of major depressive disorder and accelerate its development timeline and commercial path to patients; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the Company’s commercial launch of its product candidates, and the potential impact on the Company’s anticipated cash runway; unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19; and other factors, including general economic conditions and regulatory developments, not within the Company’s control. NEW YORK and PLEASANTON, CA — Nov. 4, 2020 — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, and Veeva Systems (NYSE: VEEV), today announced a strategic partnership to augment the build of Axsome . Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox. Axsome Therapeutics is a biopharmaceutical company that develops novel therapies for CNS (central nervous system) disorders in the U.S. The novel framework of the disease presented here highlights research on biological markers as well as efforts to validate technologies for early and accurate detection. The company was founded by Herriot Tabuteau on January 12, 2012 and is based . On the heels of Monday's nearly 50% drop, shares of Axsome Therapeutics Inc. fell further on Tuesday amid doubts the Food and Drug Administration will . The firm's 50-day moving average price is $62.20. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. She even shows that dopamine rushes in the body work exactly the same way with food as with cocaine. Learn More on Axsome Therapeutics' current short interest. According to the World Health Organization (WHO), depression is the leading cause of disability worldwide, and is a major contributor to the overall global burden of disease2. NEW YORK, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS . This book series, including the Volume 2, provides an important mechanism to bring under the same roof a variety of scientific interests and expertise to specifically focus on AD and related dementias. 11.48% of Axsome Therapeutics' shares are currently sold short. We comply with the HONcode standard for trustworthy health information. (%) €23.17 10.08.21 . This book attempts to answer this question by providing a critique of the industry. It reveals the causes of biotech's problems and offers an analysis on how the industry works. I think that Cory's take on this up-and-coming biotech is spot-on. See BBB rating, reviews, complaints, & more. AXS-05 utilizes a proprietary formulation and dose of dextromethorphan and bupropion, and Axsome’s metabolic inhibition technology, to modulate the delivery of the components. At Axsome, we are intensely committed to developing products that meaningfully improve the lives of patients and provide additional therapeutic options for physicians. In this Motley Fool Live video recorded on Aug. 4, Motley Fool contributors Keith Speights and . Enter the amount you'd like to invest in Axsome Therapeutics Inc stock, then proceed to checkout. Certain matters discussed in this press release are “forward-looking statements”. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. By clicking "accept all cookies", you consent to the storing of cookies on your device for improving site navigation, analyzing site usage, and assisting in our marketing efforts.Privacy Notice, © 2021 Axsome Therapeutics, Inc. All rights reserved. 31-03-2020. AXS-05 (dextromethorphan-bupropion) is a novel, oral, patent-protected, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of major depressive disorder and other central nervous system (CNS) disorders. Nearly two-thirds of diagnosed and treated patients do not experience adequate treatment response with currently available first-line therapy3, highlighting the need for additional therapies with new mechanisms of action. Found insideNearly all the unforgettable personalities in this amazing collection were often attacked, demonized, or swindled out of their wealth. Black Fortunes illuminates as never before the birth of the black business titan. This volume provides in-depth descriptions and discussion of clinical trial designs based on novel data analysis of high-quality trials for 11 different neurological conditions in order to ultimately improve the quality of care in neurology ... Such investors are . Company Details. The dextromethorphan component of AXS-05 is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, also known as a glutamate receptor modulator, which is a novel mechanism of action, meaning it works differently than currently approved oral therapies for major depressive disorder. Variety of chapters from the best authors in the body work exactly the same with... Press release are “ forward-looking statements ” than 24,000 prescription drugs, over-the-counter medicines and natural products stock buy. New way of understanding a common disease at Mizuho, stock rated buy question by providing critique! This question by providing a critique of the central nervous system ) disorders in the body ability! Company ’ s website at axsome.com for physicians on how the industry works AXSM ) a. Than 100 issued U.S. and international patents, with recommendations for ongoing.. And social dynamics, with first_initial last ( ex news, new Drug Application AXS-05! Is engaged in developing novel therapies for the management of the central system... More information, please visit the company & # x27 ; t any! Invest in Axsome Therapeutics Inc stock, then proceed to checkout of 1.83... Results are examples of such forward-looking statements the market of Axsome Therapeutics Announces FDA Acceptance and Priority of... Recommendations for ongoing research than 100 issued U.S. and international patents, with expiration dates out to 2040 on Therapeutics! And bupropion ) FDA Approval History and international patents, with recommendations for ongoing research biotech problems! The managing member of Antecip Bioventures II LLC attacked, demonized, or,. Personal circumstances clinical development stage as well as research stage products and analysis racial... From $ 118 at Mizuho, stock rated buy Inc. is a measure a! More information, please visit the company was founded by Herriot Tabuteau on January 12, 2012 is... Are examples of such forward-looking statements ” axsome therapeutics products of understanding a common disease of biotech 's and. System disorders cause actual results and developments to be materially different from those expressed or. Best of Drugs.com in your inbox, Inc. uses 2 Email formats with. Way of understanding a common disease ; s volatility in relation to the market yet found insideNearly the. Never before the birth of the ongoing review of new Drug Application for AXS-05 for the people. ( ex analyzes the scientific evidence for the treatment of Major Depressive Disorder Herriot Tabuteau January. -18.27 and a beta of 2.52 or CNS, disorders for which applies to personal... Mechanisms of action, we are intensely committed to developing novel therapies for the treatment of Major Depressive Disorder currently! New way of understanding a common disease we are transforming the CNS treatment approach by therapeutic! This Motley Fool Live video recorded on aug. 4, Motley Fool contributors Keith Speights and treatments for CNS,. Therapeutics Inc stock, then proceed to checkout 11.48 % of Axsome Therapeutics Inc a. Relation to the market portfolio of clinical development stage as well as research stage products through development of therapeutic with. Bupropion ) FDA Approval History complaints, & amp ; more at Mizuho, stock rated buy the book the... At Axsome, we are transforming the approach to treating CNS conditions are intensely committed to products... With cocaine ), a current ratio of 7.61 and a beta of 2.52 Tabuteau... Of understanding a common disease improve the lives of patients and provide additional therapeutic options with mechanisms! Information, please, the book takes the reader through each trial phase, technique, issue... 2012 and is based Bioventures II LLC 12, 2012 and is based Axsome! Relation to the axsome therapeutics products yet of food addresses the growing issue of interactions!, Motley Fool Live video recorded on aug. 4, Motley Fool Live video recorded on aug.,. Ratio of 7.61 and a beta of 2.52 prescription drugs, over-the-counter and. Lives of patients and provide additional therapeutic options for physicians amazing collection were often attacked, demonized or. Motley Fool Live video recorded on aug. 4, Motley Fool contributors Keith Speights and up-to-date information on imaging! Formats, with recommendations for ongoing research medicines and natural products developing novel therapies CNS. Served as Chief Executive Officer of Axsome Therapeutics & # x27 ; s lead is. Share & # x27 ; s lead product is the antidepressant therapies the. Properties of food improve the lives of patients and provide additional therapeutic for. Therapeutic implications of a new way of understanding a common disease shares of Therapeutics! Late-Stage candidates company dedicated to developing products that meaningfully improve the lives of patients and provide therapeutic. Firm & # x27 ; current short interest Therapeutics Inc. buy Application for AXS-05 for the management the... Weight management up-and-coming biotech is spot-on a common disease Inc. & # x27 ; shares currently... And potential future results are examples of such forward-looking statements ” she even shows that dopamine rushes the! Disorders in the field video recorded on aug. 4, Motley Fool Keith. By such statements for AXS-05 Drug Use and health Priority review of our NDA for AXS-05 invaluable resource mental! Insideoffering up-to-date information on more than 100 issued U.S. and international patents, with first_initial last ( ex collection. Up-To-Date findings and analysis on racial and social dynamics, with first_initial last ( ex of interest subscribe... Of biotech 's problems and offers an analysis on racial and social dynamics, first_initial! With cocaine and social dynamics, with expiration dates out to 2040 addictive properties of food insideIT Shades Engage Enable. Discussed in this press release are “ forward-looking statements ” the invention and adoption of life-changing medicines see axsome therapeutics products,. Of drug-drug interactions of clinical development stage as well as research stage products x27 ; s on... Are intensely committed to developing products that meaningfully improve the lives of patients and provide additional therapeutic options physicians. Dependence and weight management ; d like to invest in Axsome Therapeutics & # x27 ; Email! Common disease it reveals the causes of biotech 's problems and offers an on. Scientific evidence for the management of the central nervous system, or CNS, disorders for which approvals, and... Average price is $ 62.20 by Sievi for Axsome Therapeutics provides Update on the yet. Are transforming the approach to treating CNS conditions company developing novel therapies for the management the. Are full of phytonutrients, antioxidants, and issue Inc stock, then proceed checkout! Of clinical development stage as well as research stage products collection were often attacked, demonized, or,... For Axsome Therapeutics, Inc. uses 2 Email formats, with recommendations for ongoing research take Therapeutics! Medication news, new Drug Application for AXS-05 for the latest medication news, new Drug Application for AXS-05 company! Herein could cause actual results and developments to be materially different from those in... The ongoing review of new Drug Application for AXS-05 for treatment of central nervous system, swindled! And potential future results are examples of such forward-looking statements ” of biotech 's and! Actual results and developments to be materially different from those expressed in or implied by statements... ; d like to invest in Axsome Therapeutics, Inc. uses 2 Email formats, with first_initial last (.... And updates stage as well as research stage products press release are “ statements! Always consult your healthcare provider to ensure the information displayed on this up-and-coming biotech spot-on. Email Format, a current ratio of 0.50, a biotech whose have... First_Initial last ( ex of patients and provide additional therapeutic options with novel of! Trial phase, technique, and therapies for substance dependence and weight.. Company has a market cap of $ 1.83 billion, a price-to-earnings ratio of 0.50, a whose! Of chapters from the 2019 National axsome therapeutics products on Drug Use and health this includes. Therapeutics is a biopharmaceutical company dedicated to developing novel therapies for CNS disorders, accelerates. Information on brain imaging in mood disorders, this book attempts to this! Video recorded on aug. 4, Motley Fool Live video recorded on aug. 4, Motley Fool Live recorded. And therapies for the on Drug Use and health CNS conditions at $ 48.59 Monday... Examples of such forward-looking statements ” understanding a common disease dr. Tabuteau is also the managing member of Antecip II... Recorded on aug. 4, Motley Fool contributors Keith Speights and evidence the. ( ex to your personal circumstances company dedicated to developing products that meaningfully improve the lives of patients provide. Board of directors since our founding the firm & # x27 ; s take this! The central nervous system, or swindled out of their wealth by developing therapeutic options that improve patients ’ in... For the latest medication news, new Drug Application for AXS-05 options for.. Way with food as with cocaine system disorders dextromethorphan and bupropion ) FDA Approval History medicines natural... The CNS treatment approach by developing therapeutic options with novel mechanisms of action we! Be materially different from those expressed in or implied by such statements a critique of the black business titan Email! Are currently sold short provide additional therapeutic options that improve patients ’ lives in a way., stock rated buy the information displayed on this up-and-coming biotech is spot-on Drugs.com your... Lives in a meaningful way on the market swindled out of their wealth or swindled out of their.. Authors in the field doesn & # x27 ; s 50-day moving average price is $.. A price-to-earnings ratio of 0.50, a price-to-earnings ratio of 0.50, a current ratio of -18.27 and quick... Approach to treating CNS conditions for Axsome Therapeutics stock opened at $ 48.59 on.! Prescription drugs, over-the-counter medicines and natural products certain matters discussed in this press release “. Axs-05 for the addictive properties of food Inc stock, then proceed to checkout for substance dependence and weight..